LifeStance Health Group, Inc. (LFST) is a Healthcare stock trading at $11.34 (as of 2026-07-20), with a market capitalization of $4.40B and a trailing P/E of 189.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates outpatient mental health platform as well as offers patients care virtually through its online delivery platform or in-person at its centers in 32 states. It serves children, adolescents, adults, and geriatrics. LifeStance Health Group, Inc. was founded in 2017 and is based in Scottsdale, Arizona.
LifeStance Health Group provides outpatient mental health services (psychiatric evaluations, therapy, and psychological and neuropsychological testing, in person and via virtual care), and it makes money by delivering these clinical services to patients.
Because the company’s revenue comes from providing outpatient mental health care (including evaluations, therapy, and testing, delivered in person and virtually), its profitability is fundamentally driven by how effectively it can deliver those services at scale to generate recurring service revenue.
| Total | $0.4B |
Business quality (Mixed): The business model is straightforward (outpatient mental health services, including virtual care), and the latest quarter shows a modest operating margin (5.5%). However, detailed segment disclosures and true operational KPIs beyond revenue are not provided in the available facts.
Valuation: At 150× earnings, LFST trades 498% above the Healthcare Services average (25×). Note: one-time items can distort reported P/E.
| Price | $11.34 |
| Market Cap | $4.40B |
| P/E Ratio | 189.6 |
| EV / EBITDA | 51.8 |
| Price / Book | 2.98 |
| Price / Sales | 2.94 |
| FCF Yield | 3.2% |
| DCF Value (model) | $2.78 |
| DCF Upside vs Price | -75.5% |
| Revenue (TTM) | $1.42B |
| Net Margin | 0.7% |
| Revenue Growth (YoY) | 21.2% |
| FCF Growth (YoY) | -317.8% |
| Altman Z-Score | 4.14 (safe) |
| Stock P/E | 189.6 |
| Sector P/E (Healthcare) | 21.1 |
| Industry P/E (Healthcare Services) | 28.9 |
| vs Sector | 800.3% |
| vs Industry | 556.3% |
| Top Institutional Holder | TPG GP A, LLC ($891.97M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Healthcare Services |
| CEO | David Patrick Bourdon |
| Employees | 7,535 |
| Country | US |
| IPO Date | 2021-06-10 |
Data as of 2026-07-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.